VDAC2 brake release: unleashing inflammation via IFNγ
- 29 July 2025
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 46 (8) , 695-696
Abstract
No abstract availableKeywords
Funding Information
- Welch Foundation
- Cancer Research UK
- Howard Hughes Medical Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Cancer Institute
- Dermatology Foundation
This publication has 7 references indexed in Scilit:
- VDAC2 loss elicits tumour destruction and inflammation for cancer therapyNature, 2025
- ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunityCell, 2024
- The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell deathMolecular Cell, 2024
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon PathwayScience, 2013
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNAScience, 2013
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- VDAC2 Inhibits BAK Activation and Mitochondrial ApoptosisScience, 2003